((自动化翻译由路透提供，请见免责声明 ))
10月16日 - ** 为罕见神经系统疾病开发基因疗法的 Voyager Therapeutics 股价上涨 10.5%，报 8 美元
** 券商Leerink Partners开始对VYGR进行评级，评级为 "跑赢大盘"，目标价为15美元。
** 券商称 Voyager 的基因疗法运载工具 TRACER 具有独特的机制，使其从其他平台中脱颖而出。
** Leerink 称，VYGR 正在开发用于治疗罕见神经系统疾病的平台，该平台在各种动物实验中显示出更强的大脑穿透力，很有可能在人体试验中得到验证。
** 经纪公司称，该公司基因治疗工具许可交易产生的现金流被严重低估。
** Leerink 还认为该公司的阿尔茨海默病临床项目有可能取得成功并开展更多合作
** 10家券商中有9家将股票评级定为 "买入 "或更高，1家为 "持有"；PT中值为18美元 - LSEG
** 包括盘中走势在内，该股今年累计下跌 10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.